Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

558.87
+13.412.46%
Post-market: 562.994.12+0.74%19:55 EDT
Volume:1.66M
Turnover:920.76M
Market Cap:60.34B
PE:14.17
High:583.28
Open:583.01
Low:542.89
Close:545.46
Loading ...

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
02 Jul

Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy

MT Newswires Live
·
30 Jun

Bayer AG's Eylea™ 8 mg Receives EU Approval for Extended 6-Month Treatment Intervals in Retinal Diseases

Reuters
·
27 Jun

Regeneron Pharmaceuticals Inc. to Announce Second Quarter 2025 Financial and Operating Results

Reuters
·
27 Jun

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Jun

Sanofi SA Announces Breakthrough Results: Dupixent Outperforms Xolair in Phase 4 Study for Chronic Rhinosinusitis with Nasal Polyps and Asthma

Reuters
·
24 Jun

Regeneron announces donation matching program with Good Days

TIPRANKS
·
24 Jun

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Reuters
·
21 Jun

Sector Update: Health Care Stocks Rise Premarket Friday

MT Newswires Live
·
20 Jun

Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease

MT Newswires Live
·
20 Jun

Regeneron Pharmaceuticals Inc. Concluded Annual Shareholders Meeting

Reuters
·
19 Jun

Sector Update: Health Care Stocks Fall in Afternoon Trading

MT Newswires Live
·
18 Jun

Market Chatter: Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

MT Newswires Live
·
17 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

US Pharma Bets Big on China to Snap up Potential Blockbuster Drugs

Reuters
·
17 Jun

BRIEF-Regeneron Pharmaceuticals says declined to submit new bid on 23andMe exceeding original $256 mln

Reuters
·
17 Jun

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
17 Jun

Silver Scott Health Unveils Health Trust NFT, Empowering Patients with Data Control

Reuters
·
16 Jun

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million

MT Newswires Live
·
16 Jun

Regeneron Pharmaceuticals Announces Positive Phase 4 Trial Results: Dupixent® Outperforms Xolair® in Treating Chronic Rhinosinusitis with Nasal Polyps and Asthma

Reuters
·
15 Jun